Clinical Trials Logo

LRTI clinical trials

View clinical trials related to LRTI.

Filter by:
  • None
  • Page 1

NCT ID: NCT05921526 Not yet recruiting - Pneumonia Clinical Trials

Effectiveness of Point-of-care Lung Ultrasound for the Management of Childhood Lower Respiratory Infections

ELUS
Start date: January 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness of point-of-care lung ultrasound versus chest X-ray for the management of childhood lower respiratory infections in a low-resource setting. The main question it aims to answer is: Is point-of-care lung ultrasound as effective as chest X-ray for the management of childhood LRIs in a low-resource setting? Participants will be assigned to either a point-of-care lung ultrasound group (intervention) or a chest X-ray group (control), to compare the effect on overall case management and various clinical outcomes (time to symptom resolution, rate of antibiotic use, length of stay, treatment costs).

NCT ID: NCT05063149 Recruiting - Premature Clinical Trials

Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.

PROTEA
Start date: January 18, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to reduce respiratory tract infections and wheezing in moderate-late preterms in the first year of life by bacterial lysate administration. Next to determine the correlation of biological markers with respiratory symptoms, immune protection and treatment effect.

NCT ID: NCT03109106 Completed - LRTI Clinical Trials

Procalcitonin for Stewardship in Respiratory Infections A Stewardship Project

Start date: April 15, 2017
Phase: N/A
Study type: Interventional

Antibiotics are overused in hospitals nationwide, leading to unnecessary drug costs and adverse events. Antibiotic stewardship is now a national and international priority and regulatory authorities are mandating antibiotic stewardship programs in all hospitals. Respiratory infections account for a large percentage of antibiotic overuse. Procalcitonin has been shown to help providers significantly shorten the duration of antibiotic therapy in respiratory infections. As such, this institution seeks to evaluate the impact of PCT-guided antibiotic management on antibiotic use in subjects with acute Lower Respiratory Tract Infection (LRTI) with or without sepsis. Multiple studies have been conducted in Europe and demonstrate the safety of the PCT-guided antibiotic management in pneumonia as well as sepsis. This study will apply PCT-guided therapy to those populations in an all-US study evaluating patient outcomes along with safety and efficacy.

NCT ID: NCT02025699 Completed - Sepsis Clinical Trials

Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis

TailoredT
Start date: February 2014
Phase: N/A
Study type: Observational

The TAILORED-Treatment consortium was established to develop new tools aimed to increase the effectiveness of antibiotic and antifungal therapy, reduce adverse events, and help limit the emergence of antimicrobial resistance in children and adults.

NCT ID: NCT01917461 Completed - Gastroenteritis Clinical Trials

Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections

CURIOSITY
Start date: September 2010
Phase: N/A
Study type: Observational

This is an observational prospective study of an in-vitro diagnostic (IVD) assay planned to enroll 632 subjects. The study will be conducted in two stages: Stage A is aimed at identifying individual biomarkers and constructing a multi-parametric diagnostic model, whereas Stage B is aimed at testing the multi-parametric diagnostic model using a fresh cohort of patients. A collection of clinical, radiological and laboratory data will be gathered in order to establish a final diagnosis. Blood samples will be analyzed and the levels of approximately 700 and 250,000 biomarkers will be determined using immunoassays and molecular measurements respectively. A final diagnosis will be determined based on a majority decision of a panel of three or more independent physicians. Based on the final diagnosis, the accuracy of individual biomarkers and combined sets of biomarkers for differentiating between distinct groups of patients will be evaluated.